A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Clinical trial NCT05232851 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05232851
Sponsor: Mayo Clinic
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Human Papillomavirus-Related Carcinoma Locally Advanced Oropharyngeal Carcinoma Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Start date: 2022-06-16
Primary completion: 2025-04-09
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.